Loading…

Sandoz Group LtdSDZ.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Pharmaceuticals: Major

Swiss generic-drug and biosimilar maker spun off from Novartis, selling off-patent medicines worldwide.

≈ A generics/biosimilars peer of ViatrisMomentum leader 83
Mkt cap
$41.7B
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$110M
20-day average traded
Fwd P/E
24.5×
forward earnings
ROIC−WACC
+5.0 pp
WACC 5.0%
Hurdle
+7 pp
Req g minus delivered
Official | Implied
BBB / A-
agencies · bond market
Next earnings
91 days
17 Feb 2027
Close · CHFCHF 81.50
1D-1.8%
1W-4.3%
1M+5.7%
3M+10.4%
6M+25.8%
YTD+40.9%
1Y+48.6%
ATR %2.6%
52w lowhigh6.2% off high

What Sandoz does

Swiss generic-drug and biosimilar maker spun off from Novartis, selling off-patent medicines worldwide.

Sells off-patent medicines mainly to hospitals, pharmacies and health systems that buy by tender, so price and supply reliability win business; Europe is its largest region. Biosimilars, near copies of biotech drugs that have lost patent protection, are the growth line and include versions of Humira and denosumab.

In one line: A generics/biosimilars peer of Viatris.

Products and services

  • Generics
  • Biosimilars
  • Anti-infectives

Customers

  • Hospitals
  • Pharmacies
  • Health insurers/payers
  • Governments

Where it sits in the supply chain

  • Pharmaceuticals
  • Off-patent medicines
  • Generics & biosimilars manufacturing

What could go right

  • Patent-cliff wave of biologics going off-patent
  • Biosimilar share gains in US/Europe

What could go wrong

  • Pricing pressure/tenders
  • Biosimilar competition intensifying

Moat: narrow (scale, regulatory licence). Large manufacturing footprint and biosimilar approvals are costly to replicate, but products are largely undifferentiated.

Headquarters: Basel, Switzerland · Founded: 1886 · Employees: 23,000

Named competitors

Sandoz at a glance

Size Sandoz (SDZ.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $41.7B, the 14th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 81.50 on 18 Nov 2026.

Performance Over six months the shares gained 25.8%, against +16.9% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 0.8% over the last twelve months (peer median +14.0%); the operating margin is 15.2% (peer median 19.0%).

Valuation It trades at 24.5× forward earnings against a peer median of 17.9× (8th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 5.0 points above its cost of capital (5.0% WACC).

Credit Sandoz has 8 bonds outstanding ($4.66B), rated BBB by the agencies and trading like A- at a weighted spread of 100 bp.

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026SDZ.SW 126Peer median 115
Six months, rebased to 100: Sandoz against the median of its 20 peers (local-currency closes).

Sandoz financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 9.21BCHF 9.21BCHF 9.12BCHF 8.94BCHF 8.86B
Revenue growth—+1%+2%+1%—
Gross profitCHF 4.38BCHF 4.33BCHF 4.31BCHF 4.07BCHF 4.15B
EBITDACHF 1.87BCHF 1.81BCHF 1.80BCHF 1.57BCHF 1.77B
Net incomeCHF 515MCHF 759MCHF 0CHF 69.2MCHF 810M
Free cash flowCHF 1.08BCHF 914MCHF 222M-CHF 1.80MCHF 903M
Capital expenditureCHF 762MCHF 657MCHF 526MCHF 568MCHF 408M
Total debtn/aCHF 4.50BCHF 4.40BCHF 3.84BCHF 309M

Quarterly statements and history in the cockpit →

Sandoz competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%+20%4578HLNRPRX1276688235BIIBSUNPHARMAZTSGALD45034568DIVISLABBAYNROIV2359INSM4502MRKINCYSDZ.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Sandoz is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%+40%20×40×60×4578HLNRPRX1276688235BIIBSUNPHARMAZTSGALD45034568DIVISLAB235936924502INCYSDZ.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sandoz is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%4578HLNRPRX688235SUNPHARMAZTSGALD45034568DIVISLABINCYSDZ.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sandoz is the large dot.

Sandoz competitors and peer comparison

Head to head with its named competitors (SDZ.SW vs VTRS vs TEVA vs SUNPHARMA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sandoz SDZ.SW$41.7B+26%+1%15%24.5×7.5%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
Sun Pharmaceutical Industries SUNPHARMA.NS$48.0B-1%+12%23%36.0×28.7%
Fresenius SE & Co. KGaA FRE.DE$32.7B+41%+7%10%14.7×7.0%
Hikma Pharmaceuticals HIK.L$4.58B+15%+2%20%9.8×2.0%

How Sandoz compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sandoz against its 20 peers (data as of 18 Nov 2026)
MeasureSDZ.SWPeer medianRank in peer set
1-month return+5.7%+5.7%11th highest of 21
6-month return+25.8%+16.9%7th highest of 21
Distance from 52-week high-6.2%-8.7%9th highest of 21
Revenue growth (TTM)+0.8%+14.0%3rd lowest of 21
Operating margin15.2%19.0%6th lowest of 21
Forward P/E24.5×17.9×8th most expensive of 19
Growth the price implies (Req g, 7 yrs)7.5%8.4%7th least demanding of 18
Growth delivered (Del g)+0.4%+8.9%2nd lowest of 18
Hurdle (Req g minus delivered)+7.1 pp+0.2 pp7th most demanding of 18
ROIC minus cost of capital+5.0 pp+4.4 pp10th highest of 21
EV / EBITDA21.0×14.8×8th most expensive of 17
Net debt / EBITDA2.1×0.7×6th most indebted of 17
Bond spread100 bp88 bp3rd widest of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Jiangsu Hengrui Pharmaceuticals 1276.HKHong Kong$44.9B-24%+11%27%28.1×9.1%+2.0%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Wuxi Apptec 2359.HKHong Kong$64.1B+51%+38%44%19.5×8.4%+20.4%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%

Sandoz bonds and credit

Sandoz has 8 bonds outstanding with $4.66B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 3.77%, a spread of 100 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Sandoz's main competitors?
Named competitors: Viatris (VTRS), Teva Pharmaceutical (TEVA), Sun Pharmaceutical (SUNPHARMA.NS), Fresenius Kabi (FRE.DE), Hikma Pharmaceuticals (HIK.L). The cockpit's measured peer set (industry) also includes Otsuka Hldgs (4578.T), Haleon (HLN.L), Royalty Pharma (RPRX), Jiangsu Hengrui Pharmaceuticals (1276.HK), BeOne Medicines (688235.SS), Biogen (BIIB).
Is Sandoz expensive compared with its peers?
On forward p/e it trades at 24.5× against a peer median of 17.9×, 8th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Sandoz stock performed?
Over six months to 18 Nov 2026 the shares returned +25.8% against +16.9% for the median peer; over one year +48.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.